Custom Search


Thursday 06 December 2007

Multicomponent kinetic spectrophotometric determination of pefloxacin and norfloxacin in pharmaceutical preparations and human plasma samples with the aid of chemometrics.

By: Ni Y, Wang Y, Kokot S.

Spectrochim Acta A Mol Biomol Spectrosc 2007 Oct;(): [Epub ahead of print]

A spectrophotometric method for the simultaneous determination of the important pharmaceuticals, pefloxacin and its structurally similar metabolite, norfloxacin, is described for the first time. The analysis is based on the monitoring of a kinetic spectrophotometric reaction of the two analytes with potassium permanganate as the oxidant. The measurement of the reaction process followed the absorbance decrease of potassium permanganate at 526nm, and the accompanying increase of the product, potassium manganate, at 608nm. It was essential to use multivariate calibrations to overcome severe spectral overlaps and similarities in reaction kinetics. Calibration curves for the individual analytes showed linear relationships over the concentration ranges of 1.0-11.5mgL(-1) at 526 and 608nm for pefloxacin, and 0.15-1.8mgL(-1) at 526 and 608nm for norfloxacin. Various multivariate calibration models were applied, at the two analytical wavelengths, for the simultaneous prediction of the two analytes including classical least squares (CLS), principal component regression (PCR), partial least squares (PLS), radial basis function-artificial neural network (RBF-ANN) and principal component-radial basis function-artificial neural network (PC-RBF-ANN). PLS and PC-RBF-ANN calibrations with the data collected at 526nm, were the preferred methods-%RPE(T) approximately 5, and LODs for pefloxacin and norfloxacin of 0.36 and 0.06mgL(-1), respectively. Then, the proposed method was applied successfully for the simultaneous determination of pefloxacin and norfloxacin present in pharmaceutical and human plasma samples. The results compared well with those from the alternative analysis by HPLC.

Use of this site is subject to the following terms of use